Kintor Pharmaceutical : Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use

Kintor Pharmaceutical : Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use

Suzhou, November 24, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the top-line results for its phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne in China, which demonstrated the good safety, tolerability and pharmacokinetics … Read more